ArticleFrontiers in immunology2026

Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy versus gemcitabine and nab-paclitaxel as first-line treatment for recurrent or metastatic pancreatic ductal adenocarcinoma: a randomized, open-label, multicenter, phase III clinical trial (WGOG-PAN 006/ICSBR-2).

Xin Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.